SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Madland TM, Apalset EM, Johannessen AE, Rossebo B, Brun JG. Prevalence, disease manifestations, and treatment of psoriatic arthritis in western Norway. J Rheumatol 2005; 32: 191822.
  • 2
    Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005; 64 Suppl 2: ii147.
  • 3
    Leonard DG, O'Duffy JD, Rogers RS. Prospective analysis of psoriatic arthritis in patients hospitalized for psoriasis. Mayo Clin Proc 1978; 53: 5118.
  • 4
    Gladman DD. Psoriatic arthritis. Baillieres Clin Rheumatol 1995; 9: 31929.
  • 5
    Shbeeb M, Uramoto KM, Gibson LE, O'Fallon WM, Gabriel SE. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982–1991. J Rheumatol 2000; 27: 124750.
  • 6
    Leung YY, Tam LS, Kun EW, Li EK. Psoriatic arthritis as a distinct disease entity. J Postgrad Med 2007; 53: 6371.
  • 7
    Husted JA, Gladman DD, Farewell VT, Cook RJ. Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum 2001; 45: 1518.
  • 8
    Gladman DD, Farewell VT, Wong K, Husted J. Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 1998; 41: 110310.
  • 9
    Gladman DD, Stafford-Brady F, Chang CH, Lewandowski K, Russell ML. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol 1990; 17: 80912.
  • 10
    Mease PJ. Assessing the impact of psoriatic arthritis on patient function and quality of life: lessons learned from other rheumatologic conditions. Semin Arthritis Rheum 2009; 38: 32035.
  • 11
    Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004; 9: 1369.
  • 12
    Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005; 64: 11507.
  • 13
    Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Arthritis Rheum 2005; 52: 122736.
  • 14
    Genovese MC, Mease PJ, Thomson GT, Kivitz AJ, Perdok RJ, Weinberg MA, et al. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol 2007; 34: 104050.
  • 15
    Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356: 38590.
  • 16
    Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004; 50: 226472.
  • 17
    Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, et al, for the Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52: 327989.
  • 18
    Heiberg MS, Kaufmann C, Rodevand E, Mikkelsen K, Koldingsnes W, Mowinckel P, et al. The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study. Ann Rheum Dis 2007; 66: 103842.
  • 19
    Han C, Smolen JS, Kavanaugh A, van der Heijde D, Braun J, Westhovens R, et al. The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases. Arthritis Res Ther 2007; 9: R103.
  • 20
    Silman A, Symmons D, Scott DG, Griffiths I. British Society for Rheumatology Biologics Register. Ann Rheum Dis 2003; 62 Suppl 2: ii289.
  • 21
    Kyle S, Chandler D, Griffiths CE, Helliwell P, Lewis J, McInnes I, et al. Guideline for anti-TNF-α therapy in psoriatic arthritis. Rheumatology (Oxford) 2005; 44: 3907.
  • 22
    Electronic Medicines Compendium. Enbrel 25 mg powder and solvent for solution for injection: summary of product characteristics. 2009. URL: http://emc.medicines.org.uk/medicine/3343/SPC/Enbrel+25+mg+powder+and+solvent+for+solution+for+injection/.
  • 23
    Electronic Medicines Compendium. Humira 40 mg solution for injection in pre-filled syringe: summary of product characteristics. 2009. URL: http://emc.medicines.org.uk/medicine/21201/SPC/Humira+Pen+and+Syringe/.
  • 24
    Electronic Medicines Compendium. Remicade 100 mg powder for concentrate for solution and infusion: summary of product characteristics. 2009. URL: http://emc.medicines.org.uk/medicine/3236/SPC/Remicade+100mg+powder+for+concentrate+for+solution+for+infusion/.
  • 25
    Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight–joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 448.
  • 26
    Kirwan JR, Reeback JS. Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. Br J Rheumatol 1986; 25: 2069.
  • 27
    Ware JE Jr, Snow KK, Kosinski M, Gandek B. SF-36 health survey: manual and interpretation guide. Boston: The Health Institute, New England Medical Center; 1993.
  • 28
    Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002; 21: 27192.
  • 29
    Van Buren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med 1999; 18: 68194.
  • 30
    Royston P. Multiple imputation of missing values. Stata J 2004; 4: 22741.
  • 31
    Dupont WD. Simple linear regression. In: Statistical modeling for biomedical researchers: a simple introduction to the analysis of complex data. 1st ed. Cambridge (UK): Cambridge University; 2002. p. 4596.
  • 32
    Saad AA, Ashcroft DM, Watson KD, Hyrich KL, Noyce PR, Symmons DP. Persistence with anti-TNF therapies in patients with psoriatic arthritis: observational study from the BSR Biologics Register. Arthritis Res Ther 2009; 11: R52.
  • 33
    Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993; 20: 55760.
  • 34
    Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE Jr. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000; 43: 147887.
  • 35
    Heiberg MS, Nordvag BY, Mikkelsen K, Rodevand E, Kaufmann C, Mowinckel P, et al. The comparative effectiveness of tumor necrosis factor–blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study. Arthritis Rheum 2005; 52: 250612.
  • 36
    Heiberg MS, Koldingsnes W, Mikkelsen K, Rodevand E, Kaufmann C, Mowinckel P, et al. The comparative one-year performance of anti–tumor necrosis factor α drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum 2008; 59: 23440.
  • 37
    Gladman DD, Mease PJ, Cifaldi MA, Perdok RJ, Sasso E, Medich J. Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial. Ann Rheum Dis 2007; 66: 1638.
  • 38
    De Felice C, Mazzotta A, Esposito M, Bianchi L, Chimenti S. High-dose initiation of etanercept in psoriatic arthritis and plaque psoriasis: efficacy, safety and impact on patients' quality of life. J Dermatolog Treat 2006; 17: 3558.
  • 39
    Fransen J, Antoni C, Mease PJ, Uter W, Kavanaugh A, Kalden JR, et al. Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomized, controlled trials of two TNF inhibitors. Ann Rheum Dis 2006; 65: 13738.
  • 40
    Kristensen LE, Gulfe A, Saxne T, Geborek P. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register. Ann Rheum Dis 2008; 67: 3649.
  • 41
    Gulfe A, Kristensen LE, Saxne T, Jacobsson LT, Petersson IF, Geborek P. Rapid and sustained health utility gain in anti-TNF treated inflammatory arthritis: observational data during seven years in southern Sweden. Ann Rheum Dis 2009. E-pub ahead of print.
  • 42
    National Institute for Health and Clinical Excellence. NICE technology appraisal guidance 104: etanercept and infliximab for the treatment of adults with psoriatic arthritis. 2006. URL: http://www.nice.org.uk/TA104.
  • 43
    National Institute for Health and Clinical Excellence. NICE technology appraisal guidance 125: adalimumab for the treatment of psoriatic arthritis. 2007. URL: http://www.nice.org.uk/TA125.
  • 44
    McKenna SP, Doward LC, Whalley D, Tennant A, Emery P, Veale DJ. Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis. Ann Rheum Dis 2004; 63: 1629.
  • 45
    Gladman DD, Mease PJ, Strand V, Healy P, Helliwell PS, Fitzgerald O, et al. Consensus on a core set of domains for psoriatic arthritis. J Rheumatol 2007; 34: 116770.
  • 46
    Taylor WJ. Assessment of outcome in psoriatic arthritis. Curr Opin Rheumatol 2004; 16: 3506.
  • 47
    Baltussen R, Leidl R, Ament A. Real world designs in economic evaluation: bridging the gap between clinical research and policy-making. Pharmacoeconomics 1999; 16: 44958.
  • 48
    Barton GR, Sach TH, Avery AJ, Jenkinson C, Doherty M, Whynes DK, et al. A comparison of the performance of the EQ-5D and SF-6D for individuals aged > or = 45 years. Health Econ 2008; 17: 81532.
  • 49
    Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 13745.
  • 50
    Leung YY, Tam LS, Kun EW, Ho KW, Li EK. Comparison of 4 functional indexes in psoriatic arthritis with axial or peripheral disease subgroups using Rasch analyses. J Rheumatol 2008; 35: 161321.
  • 51
    Blackmore MG, Gladman DD, Husted J, Long JA, Farewell VT. Measuring health status in psoriatic arthritis: the Health Assessment Questionnaire and its modification. J Rheumatol 1995; 22: 88693.
  • 52
    Husted JA, Gladman DD, Cook RJ, Farewell VT. Responsiveness of health status instruments to changes in articular status and perceived health in patients with psoriatic arthritis. J Rheumatol 1998; 25: 214655.
  • 53
    Aletaha D, Smolen J, Ward MM. Measuring function in rheumatoid arthritis: identifying reversible and irreversible components. Arthritis Rheum 2006; 54: 278492.
  • 54
    Hyrich KL, Lunt M, Dixon WG, Watson KD, Symmons DP. Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug. Rheumatology (Oxford) 2008; 47: 10005.